Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
MWN-AI** Summary
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology firm focused on treating serious diseases through innovative gene expression correction, has appointed Ryan Maynard as its Chief Financial Officer (CFO), effective February 23, 2026. With over 25 years of experience in the biopharmaceutical sector, Maynard brings a robust background in financial strategy and operational leadership, having served in executive roles at both public and private companies. His previous tenure as CFO at Cara Therapeutics notably involved leading financial strategies and executing strategic transactions, including a successful reverse merger.
Foghorn's President and CEO, Adrian Gottschalk, expressed enthusiasm about Maynard joining the team at a critical juncture, emphasizing his extensive experience in scaling organizations, which is essential for advancing Foghorn's first-in-class therapeutic pipeline. Maynard himself conveyed excitement about joining Foghorn, highlighting the company's lead program's progress in dose escalation and its innovative selective degrader portfolio approaching clinical trials. His role will focus on providing disciplined financial leadership and supporting long-term growth and value creation.
Ryan Maynard's impressive career also includes significant achievements such as raising over $1 billion through public and private financings, playing a pivotal role in the FDA approval of TAVALISSE®, and executive involvement in KORSUVA®'s commercial launch. Prior to Cara Therapeutics, he served as CFO at Rigel Pharmaceuticals, LetsGetChecked, and Blade Therapeutics, alongside currently sitting on the board of Iovance Biotherapeutics.
Foghorn Therapeutics is dedicated to developing novel medicines that target the chromatin regulatory system through its Gene Traffic Control® platform, focusing on genetically driven dependencies primarily in oncology. More information about the company's endeavors can be found on its website and social media platforms.
MWN-AI** Analysis
Foghorn Therapeutics' recent announcement regarding the appointment of Ryan Maynard as Chief Financial Officer (CFO) marks a significant step in strengthening its financial leadership during a pivotal period. Maynard's extensive experience—spanning over 25 years in the biopharma sector—combined with a proven track record in financial strategy and capital markets execution makes him an asset as Foghorn navigates its advancing pipeline and prepares for potential commercialization of its products.
The appointment comes as Foghorn progresses its lead program in collaboration with Eli Lilly and ushers in its selective degrader portfolio into clinical development. This strategic alignment is crucial as it reflects Foghorn’s ambition to not just innovate, but also convert its groundbreaking research into marketable therapies, which can significantly impact shareholder value.
Investors should view Maynard's hiring as a positive signal of Foghorn’s commitment to disciplined financial leadership and robust operational execution. His history of raising over $1 billion and managing successful strategic transactions is particularly noteworthy, especially considering Foghorn's potential financial needs as it advances its product candidates through clinical trials.
However, it is essential for investors to remain vigilant as Foghorn navigates the challenges of drug development, which inherently carry risks. Factors such as regulatory hurdles, market competition, and clinical trial results can significantly impact Foghorn’s trajectory. Furthermore, the biotechnology sector often faces volatility, and investors should assess their risk tolerance accordingly.
In conclusion, while the leadership change is promising and may enhance operational efficiency and financial strategy, potential investors should conduct thorough due diligence considering both the opportunities and risks associated with investing in a clinical-stage biotechnology firm like Foghorn Therapeutics. With strategic financial leadership now in place, the company is poised for a critical phase in its growth journey.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies.
“I am delighted to welcome Ryan to Foghorn as our new CFO as we continue to advance our first-in-class pipeline," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “Ryan is a seasoned biotech executive who brings proven financial and operational leadership. His experience scaling organizations will accelerate our mission to deliver novel therapies to patients.”
Prior to joining Foghorn, Mr. Maynard was most recently at Cara Therapeutics, Inc., where he successfully led financial strategy and strategic transactions as the Chief Financial Officer.
Ryan Maynard, Chief Financial Officer of Foghorn, added, “I am excited to join Foghorn at this pivotal time as the Company’s lead program advances in dose escalation in partnership with Lilly, and our selective degrader portfolio nears the clinic. I look forward to partnering with the executive team and Board to provide disciplined financial leadership, drive execution, and support long-term growth and value creation.”
Mr. Maynard has over 25 years of executive experience leading both public and private biopharmaceutical and healthcare technology organizations. He has raised over $1 billion through public and private financings, played a key role in the Food and Drug Administration (FDA) approval and commercial launch planning of TAVALISSE®, and built strong relationships with healthcare-focused investors. Most recently at Cara Therapeutics, Inc., he successfully executed a reverse merger with Tvardi Therapeutics, raised $37.5 million through a non-dilutive royalty deal, and provided executive leadership on commercial manufacturing and launch planning for KORSUVA®. Mr. Maynard was previously the CFO at Rigel Pharmaceuticals, LetsGetChecked Inc., and Blade Therapeutics. He holds a BS in Commerce with a focus in accounting from Santa Clara University. Mr. Maynard currently serves on the board of Iovance Biotherapeutics, Inc., a commercial biotechnology company.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers, pre-clinical product candidates, expected timing of clinical data, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ**
How might the appointment of Ryan Maynard as CFO impact the financial strategy and overall growth trajectory of Foghorn Therapeutics Inc. (FHTX) in the upcoming years?
What are the specific milestones that Foghorn Therapeutics Inc. (FHTX) expects to achieve during the ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers?
Given Ryan Maynard's background, what strategies does he plan to implement at Foghorn Therapeutics Inc. (FHTX) to enhance investor engagement and capital market execution?
How does Foghorn Therapeutics Inc. (FHTX) plan to navigate the potential risks associated with its clinical trials and the broader regulatory landscape to ensure sustainable growth?
**MWN-AI FAQ is based on asking OpenAI questions about Foghorn Therapeutics Inc. (NASDAQ: FHTX).
NASDAQ: FHTX
FHTX Trading
-2.14% G/L:
$5.50 Last:
48,528 Volume:
$5.44 Open:
